CN1617857A - 2′－卤代－3′,5′－二烷氧苯－1′－基－亚氨基－2－咪唑烷衍生物及其在治疗尿失禁中的用途 - Google Patents

2′－卤代－3′,5′－二烷氧苯－1′－基－亚氨基－2－咪唑烷衍生物及其在治疗尿失禁中的用途 Download PDF

Info

Publication number
CN1617857A
CN1617857A CNA028277376A CN02827737A CN1617857A CN 1617857 A CN1617857 A CN 1617857A CN A028277376 A CNA028277376 A CN A028277376A CN 02827737 A CN02827737 A CN 02827737A CN 1617857 A CN1617857 A CN 1617857A
Authority
CN
China
Prior art keywords
imidazolidine
imino
compound
chloro
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028277376A
Other languages
English (en)
Chinese (zh)
Inventor
弗朗兹·埃瑟
帕斯卡尔·波泽特
石黑直树
喜多川久人
村松郁延
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CN1617857A publication Critical patent/CN1617857A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA028277376A 2002-01-31 2002-12-16 2′－卤代－3′,5′－二烷氧苯－1′－基－亚氨基－2－咪唑烷衍生物及其在治疗尿失禁中的用途 Pending CN1617857A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02002352A EP1333028A1 (en) 2002-01-31 2002-01-31 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
EP02002352.9 2002-01-31

Publications (1)

Publication Number Publication Date
CN1617857A true CN1617857A (zh) 2005-05-18

Family

ID=8185397

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028277376A Pending CN1617857A (zh) 2002-01-31 2002-12-16 2′－卤代－3′,5′－二烷氧苯－1′－基－亚氨基－2－咪唑烷衍生物及其在治疗尿失禁中的用途

Country Status (20)

Country Link
EP (2) EP1333028A1 (https=)
JP (1) JP2005516066A (https=)
KR (1) KR20040074134A (https=)
CN (1) CN1617857A (https=)
AR (1) AR038380A1 (https=)
BR (1) BR0215560A (https=)
CA (1) CA2474588A1 (https=)
EA (1) EA200400877A1 (https=)
EC (1) ECSP045210A (https=)
HR (1) HRP20040691A2 (https=)
HU (1) HUP0402654A2 (https=)
IL (1) IL162776A0 (https=)
MX (1) MXPA04007250A (https=)
NO (1) NO20043614L (https=)
PE (1) PE20030819A1 (https=)
PL (1) PL369826A1 (https=)
TW (1) TW200418462A (https=)
UY (1) UY27628A1 (https=)
WO (1) WO2003064398A1 (https=)
ZA (1) ZA200405173B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102099032B (zh) * 2008-06-09 2014-07-09 阿勒根公司 治疗α肾上腺素能介导的病症的方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4168086B1 (ja) * 2008-04-16 2008-10-22 国立大学法人福井大学 イミダゾリン誘導体
WO2009140137A1 (en) * 2008-05-13 2009-11-19 Allergan, Inc. Naphthylmethylimidizoles for the treatment of stress urinary incontinence
AU2009246601A1 (en) * 2008-05-13 2009-11-19 Allergan, Inc. Quinolynylmethylimidizoles as therapeutic agents
US9034910B2 (en) 2008-06-09 2015-05-19 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
US8063231B2 (en) * 2008-06-09 2011-11-22 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
EP4714422A1 (en) * 2024-09-20 2026-03-25 Società Italo Britannica L. Manetti - H. Roberts & C.p.A. Composition for absorbing skin perspiration and/or body moisture

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2220906A1 (de) * 1972-04-28 1973-11-15 Boehringer Sohn Ingelheim Neue substituierte 2-phenylaminoimidazoline-(2), deren saeureadditionssalze sowie verfahren zu deren herstellung
DE2259160A1 (de) * 1972-12-02 1974-06-06 Boehringer Sohn Ingelheim Neue substituierte 2-phenylaminoimidazoline, deren saeureadditionssalze und verfahren zur herstellung derselben sowie ihre verwendung als arzneimittel
AT333749B (de) * 1974-07-03 1976-12-10 Chemie Linz Ag Verfahren zur herstellung von neuen 2-arylamino-2-imidazolinderivaten
MTP837B (en) * 1977-11-07 1979-10-22 Hoffman La Roche And Co Aktien Derivatives 2 finino-imidazolidire
DE3514351A1 (de) * 1985-04-20 1986-11-06 Boehringer Ingelheim KG, 6507 Ingelheim Neue substituierte 2-(n-alkinyl-n-phenyl)amino)-imidazolinderivate, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
SG72827A1 (en) * 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
DE19740176C2 (de) * 1997-09-12 2000-04-06 Lemfoerder Metallwaren Ag Handschaltvorrichtung für ein Kraftfahrzeug

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102099032B (zh) * 2008-06-09 2014-07-09 阿勒根公司 治疗α肾上腺素能介导的病症的方法

Also Published As

Publication number Publication date
TW200418462A (en) 2004-10-01
ECSP045210A (es) 2004-09-28
PL369826A1 (en) 2005-05-02
WO2003064398A1 (en) 2003-08-07
EP1333028A1 (en) 2003-08-06
ZA200405173B (en) 2005-06-21
NO20043614L (no) 2004-08-30
CA2474588A1 (en) 2003-08-07
BR0215560A (pt) 2004-12-21
PE20030819A1 (es) 2003-10-20
KR20040074134A (ko) 2004-08-21
EA200400877A1 (ru) 2005-02-24
MXPA04007250A (es) 2004-10-29
EP1472231A1 (en) 2004-11-03
HRP20040691A2 (en) 2004-12-31
AR038380A1 (es) 2005-01-12
IL162776A0 (en) 2005-11-20
HUP0402654A2 (hu) 2005-03-29
UY27628A1 (es) 2003-08-29
JP2005516066A (ja) 2005-06-02

Similar Documents

Publication Publication Date Title
CN1142783C (zh) 用于治疗高危葡萄糖耐量降低的药剂
CN1119148C (zh) α1L-激动剂在制备用于治疗尿失禁的药物组合物中的用途
US8852634B2 (en) Dosage formulation
CN120284995A (zh) N4-羟基胞苷和衍生物及其相关的抗病毒用途
CN1144598C (zh) 利用氧化镁稳定的含ace抑制剂的组合物
FR2613934A1 (fr) Composition pharmaceutique a base de 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl) methyl)-4h-carbazol-4-one et de la ranitidine, son procede de fabrication, l'utilisation de ses deux principes actifs pour la fabrication d'un medicament
CN1527701A (zh) 在口腔中迅速崩解的片剂
CN1323200A (zh) 5ht4激动剂或拮抗剂的新型口服制剂
JP2024522817A (ja) フェニルピロールアミノグアニジン塩及び製剤
CN1617857A (zh) 2′－卤代－3′,5′－二烷氧苯－1′－基－亚氨基－2－咪唑烷衍生物及其在治疗尿失禁中的用途
CN1610548A (zh) 依贝沙坦在制备用来预防或治疗肺动脉高压的药物中的应用
CN1209122A (zh) 糖尿病并发症的预防/治疗药
CN1265793C (zh) 左西替利嗪伪麻黄碱复方口服制剂及制备方法
US6703409B2 (en) 2′-Halo-3′,5′-dialkoxyphen-1′-yl-imino-2-imidazolidine and the use thereof as a drug
EP4552642A1 (en) Agent for reducing blood myostatin level
CN1025330C (zh) 可用于治疗溃疡的新型丙烯酸盐的制备方法
US6683104B1 (en) Cholesterol and triglyceride-modulating drugs and methods
JP2004517158A (ja) 尿失禁を治療するための２−アミノ−１−（４−ヒドロキシ−２−メタンスルホンアミドフェニル）エタノールの使用
CN101074222A (zh) 3－取代香豆素化合物、其制法和其药物组合物与用途
CN101077868A (zh) 噻二唑取代的咪唑类抗厌氧菌化合物
CN1694692A (zh) 改善下腹和/或会阴疼痛的治疗剂
AU2002360984A1 (en) 2'-halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
HK1124249A (en) Novel dosage formulation
CN1905879A (zh) 包含单胺神经递质再摄取抑制剂和n－甲基－d－天冬氨酸(nmda)受体拮抗剂的药物组合物
HK1044713A (en) Pharmaceutical complex

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication